Divergent mechanisms underlie Smad4-mediated positive regulation of the three genes encoding the basement membrane component laminin-332 (laminin-5) by Dirk Zboralski et al.
BioMed CentralBMC Cancer
ssOpen AcceResearch article
Divergent mechanisms underlie Smad4-mediated positive 
regulation of the three genes encoding the basement membrane 
component laminin-332 (laminin-5)
Dirk Zboralski1, Miriam Böckmann1, Marc Zapatka1,4, Sabine Hoppe1, 
Anna Schöneck1, Stephan A Hahn2, Wolff Schmiegel1,3 and 
Irmgard Schwarte-Waldhoff*1
Address: 1Department of Internal Medicine, Knappschaftskrankenhaus, IMBL, Ruhr-University of Bochum, Bochum, Germany, 2Department of 
Internal Medicine, Molecular Oncology, Ruhr-University of Bochum, Bochum, Germany, 3Department of Gastroenterology and Hepatology, 
Kliniken Bergmannsheil, Ruhr-University of Bochum, Bochum, Germany and 4Department of Theoretical Bioinformatics, DKFZ, Heidelberg, 
Germany
Email: Dirk Zboralski - Dirk.Zboralski@rub.de; Miriam Böckmann - Miriam.Boeckmann@rub.de; Marc Zapatka - M.Zapatka@dkfz-
heidelberg.de; Sabine Hoppe - Sabine.Hoppe@rub.de; Anna Schöneck - Anna.Schoeneck@rub.de; Stephan A Hahn - Stephan.Hahn@rub.de; 
Wolff Schmiegel - Wolff.Schmiegel@rub.de; Irmgard Schwarte-Waldhoff* - Irmgard.Schwarte-Waldhoff@rub.de
* Corresponding author    
Abstract
Background: Functional inactivation of the tumor suppressor Smad4 in colorectal and pancreatic carcinogenesis occurs
coincident with the transition to invasive growth. Breaking the basement membrane (BM) barrier, a prerequisite for
invasive growth, can be due to tumor induced proteolytic tissue remodeling or to reduced synthesis of BM molecules by
incipient tumor cells. Laminin-332 (laminin-5), a heterotrimeric BM component composed of α3-, β3- and γ2-chains, has
recently been identified as a target structure of Smad4 and represents the first example for expression control of an
essential BM component by a tumor and invasion suppressor. Biochemically Smad4 is a transmitter of signals of the TGFβ
superfamily of cytokines. We have reported previously, that Smad4 functions as a positive transcriptional regulator of
constitutive and of TGFβ-induced transcription of all three genes encoding Laminin-332, LAMA3, LAMB3 and LAMC2.
Methods: Promoter-reporter constructs harboring 4 kb upstream regions, each of the three genes encoding Laminin-
322 as well as deletion and mutations constructs were established. Promoter activities and TGFβ induction were assayed
through transient transfections in Smad4-negative human cancer cells and their stable Smad4-positive derivatives.
Functionally relevant binding sites were subsequently confirmed through chromatin immunoprecipitation.
Results: Herein, we report that Smad4 mediates transcriptional regulation through three different mechanisms, namely
through Smad4 binding to a functional SBE site exclusively in the LAMA3 promoter, Smad4 binding to AP1 (and Sp1) sites
presumably via interaction with AP1 family components and lastly a Smad4 impact on transcription of AP1 factors.
Whereas Smad4 is essential for positive regulation of all three genes, the molecular mechanisms are significantly divergent
between the LAMA3 promoter as compared to the LAMB3 and LAMC2 promoters.
Conclusion: We hypothesize that this divergence in modular regulation of the three promoters may lay the ground for
uncoupled regulation of Laminin-332 in Smad4-deficient tumor cells in response to stromally expressed cytokines acting
on budding tumor cells.
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Functional inactivation of the tumor suppressor Smad4 in
colorectal and pancreatic carcinogenesis occurs coincident
with the transition of premalignant precursor lesions –
adenomas and pancreatic intraepithelial neoplasias
(PanINs), respectively, to invasive and metastatic growth
[1-4]. The hallmark of invasive growth is loss of the base-
ment membrane (BM) barrier. BMs are specialized sheet-
like structures of the extracellular matrix that separate epi-
thelia from the underlying mesenchyme. They are built
through interaction of epithelial and mesenchymal cells,
which both provide components, mainly the laminins
and collagen IV [5]. The epithelial-derived laminins con-
stitute a family of at least 15 different isoforms in mam-
mals, each an αxβyγz heterotrimer derived from a
combination of one, each, out of five α-, three β- and three
γ-glycoprotein subunits [6-8]. In the gastrointestinal tract
a single-layered epithelial sheet is separated from the
underlying mesenchyme through a BM containing lam-
inins- 111, -211, -332, -511 and -521 (laminins 1, 2, 5, 10
and 11), which are expressed in a characteristic regional
and development dependent pattern [5,9,10]. Also, in the
normal adult pancreas, a single layer of ductal cells – the
presumptive precursors of pancreatic adenocarcinomas, is
separated from mesenchymal cells through a BM contain-
ing laminin-332 (LM-332) [11-13].
Loss of the BM barrier upon the transition to invasive
growth can be due either to proteolytic degradation or to
decreased synthesis of BM components [14]. Proteolytic
degradation of BM in carcinomas has been intensively
investigated. It appears to be predominantly executed
through proteases expressed mainly by stromal cell types
like activated fibroblasts and inflammatory cells, which
can be recruited through signals originating from the
tumor cells. Molecular mechanisms underlying decreased
synthesis of BM components, on the other hand, have
rarely been addressed.
To unravel the mechanisms that underlie Smad4-medi-
ated tumor suppression we have established derivatives of
Smad4-deficient human colorectal and pancreatic carci-
noma cells, in which Smad4 is stably restored through
gene transfer. Using this approach we could proof
Smad4's tumor suppressor function and could identify
Smad4 target genes, among them VEGF and E-cadherin
[15-18]. Recently, we have unraveled, that LM-332, com-
posed of α3-, β3- and γ2-chains, is another relevant target
structure of Smad4. We have shown that all three genes
encoding LM-332, LAMA3, LAMB3 and LAMC2, are under
positive transcriptional control of Smad4. Smad4
increased basal and/or TGFβ-induced expression of LM-
332 in Smad4-reexpressing colon and pancreatic cancer
cells leading to a huge increase in the extracellular release
of the heterotrimer and to the deposition in BM-like struc-
tures at contact sites with fibroblasts [19].
LM-332 expression is tightly controlled in normal epithe-
lia; adenomas consistently retain normal staining patterns
for LM-332 in BMs [20]. In colorectal carcinomas, in con-
trast, laminin deposition in BM structures becomes dis-
continuous or is absent suggesting that shut-down of
laminin expression is associated with genetic alterations
that mediate the transition to invasive growth [8,14,21].
Thus, our finding that the tumor and invasion suppressor
Smad4 can act as a positive regulator of LM-332 is consist-
ent with current knowledge.
Here, we wished to further decipher the molecular mech-
anisms of how Smad4 acts as a positive transcriptional
regulator of constitutive and of TGFβ-induced expression
of the three genes encoding LM-332. Smad4 encodes an
intracellular messenger common to all signaling cascades
induced by members of the TGFβ superfamily of
cytokines through the canonical pathway [22,23]. Cellu-
lar signaling from the TGFβ family is initiated by binding
of the ligand to transmembrane receptor serine/threonine
kinases, TβRI and TβRII. Activated TGFβ receptors stimu-
late the phosphorylation of receptor-regulated Smad (R-
Smad) proteins, which in turn form complexes with
Smad4 that accumulate in the nucleus. Here, the Smad
complex can bind to DNA directly, at so-called SBE sites
(Smad binding element), but with low binding affinity,
only, and can also bind to and interact with a plethora of
other transcription factors, coactivators or corepressors
among them transcription factors of the AP1 and Sp1 fam-
ilies. High affinity binding of the Smad complex to a pro-
moter is thought to occur through the incorporation of an
additional transcription factor into the R-Smad-Smad4
complex, which binds to its respective cognate sequence
[22,23]. Adding to the complexity of cellular signaling
networks TGFβ besides the canonical pathway fuels into
further signaling cascades like the MAP kinase pathway
[24,25]. TGFβ has previously been identified as a positive
regulator of LM-332 in diverse cell types among them epi-
dermal keratinocytes and gastric adenocarcinoma cells
[26,27]. AP1 sites were found to confer TGFβ responsive-
ness of the LAMA3 and the LAMC2 promoter -encoding
for α3 and γ2-chains- in murine keratinocytes and human
colon carcinoma cells, respectively [28-31]. No reports, to
our knowledge, have yet been published addressing
molecular mechanisms of LAMB3 -encoding for β3-chain-
promoter regulation.
We have reported earlier, that an SBE site is functional and
is involved in Smad4-mediated TGFβ induction of LAMA3
expression [19]. In silico analyses detected putative SBE
sites also in the promoter regions of the LAMB3 and thePage 2 of 13
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lyzed.
Here, we present detailed studies of the three promoters of
the genes encoding LM-332 in human colorectal ade-
noma cells and in Smad4-deficient and Smad4-reexpress-
ing colorectal and pancreatic carcinoma cells. We confirm
that the SBE site at -1.5 kb confers one part of Smad4-
dependent TGFβ induction of LAMA3 expression and that
the downstream AP1 sites are additionally involved. On
the other hand, whereas each, three, putative SBE sites
were identified in the LAMB3 and the LAMC2 promoter
through in silico analyses, each of these sites proved non-
functional. Rather, TGFβ induction is conferred through
AP1-sites and through a single Sp1 site in both of these
promoters. In summary, our results show, that whereas
Smad4 functions as a positive transcriptional regulator of
all three genes encoding LM-332, the underlying mecha-
nisms are surprisingly complex and substantially diverse.
Methods
Cell culture
The human colorectal carcinoma cell line SW480 and the
human pancreatic carcinoma cell line BxPC3 cells were
obtained from the American Type Culture Collection. The
human colon adenoma cell line LT97-2 was kindly pro-
vided by M Marian (Vienna, Austria). LT97 cells were
maintained in Ham's F12 medium with supplements as
described [32]. All other cells were maintained in Dul-
becco's Modified Eagle Medium (DMEM) supplemented
with 10% fetal calf serum, 2 mM glutamine, 100 U/mL
penicillin and 100 μg/mL streptomycin.
Smad4 reconstitution and Western blot analysis
The full-length coding sequence of Smad4 was cloned
into the pBK-CMV expression vector (Stratagene) as previ-
ously described [17] and Smad4 re-expressing SW480 cell
clones and negative control transfectants were established
by retroviral transduction.
Expression of the Smad4 protein product was analyzed by
Western blotting of lysates. Cells were lysed in NP-40 lysis
buffer (25 mM Tris HCl, pH 7.4, 0.5% NP-40, 100 mM
NaCl, 1 mM EDTA) containing a protease inhibitor cock-
tail (Roche) and 1 mM PMSF. Proteins were resolved by
SDS PAGE and transferred to Immobilon membranes
(Millipore). The blots were incubated with monoclonal
antibodies against Smad4 (anti-Smad4 B8; dilution
1:500, Santa Cruz), washed with PBS containing 0.05%
Tween 20 and incubated with a secondary antibody which
was coupled with the fluorescent dye Alexa Flour 680. Sig-
nals were detected using the Odyssey Infrared Imaging
System (LI-COR Biosciences).
Vector construction and transient transfection
Promoter fragments upstream of exon1 of the human
LAMA3A; LAMB3 and LAMC2 genes were amplified by
genomic PCR with primers listed in additional file 1 and
cloned into the pGL3-basic vector (Promega). All con-
structs were sequence-verified. The 0.8 kb deletion con-
struct of the LAMC2-promoter was generated by double-
digestion of the LAMA3-2 kb construct with NheI (within
theMCS of pGL3 basic) and EcoRI. Point mutations were
introduced using the Quick-Change Site directed muta-
genesis kit (Stratagene) with the primer oligonucleotides
listed in additional file 1. DNA used for transient transfec-
tions was prepared with a plasmid Midi Kit (Qiagen,
endotoxin-free).
For transient transfections, cells were grown to a conflu-
ency of approximately 50–70% in 24-well plates and
transfected with 200/400 ng of the respective promoter
construct (pGL3-basic, Promega) and 2/4 ng internal con-
trol plasmid (phRL-SV40, Promega) using Effectene (Qia-
gen) in accordance with the manufacturer's
recommendations. TGFβ was added when indicated 5 h
after transfection at a final concentration of 5 ng/mL. The
cells were harvested after 24 h and the luciferase assays
were carried out as triplicates using a luminometer (Glo-
Max™ 96 Microplate, Promgea) and the Dual-Luciferase-
Reporter Assay System (Promega).
Chromatin immunoprecipitation
ChIP assays were performed as described in Zapatka et al.
[19] with minor modifications. BxPC3 cells were grown to
confluence in 150 mm culture dishes and treated with
recombinant TGFβ1 (R&D Systems) at a concentration of
5 ng/mL for 90 min. Proteins and DNA were crosslinked
by incubating the cells in 1% (v/v) formaldehyde at room
temperature for 10 min and the reaction was stopped by
the addition of glycine to a final concentration of 0.125
M. Cells were washed twice with Tris-buffered saline (20
mM Tris, pH 7.4, 150 mM NaCl) and lysed in SDS buffer
(50 mM Tris, pH 8.1, 0.5% (v/v) SDS, 100 mM NaCl, 5
mM ethylenediaminetetraacetic acid (EDTA), protease
inhibitors, Roche). Chromatin was pelleted by centrifuga-
tion and resuspended in 0.5 mL of immunoprecipitation
buffer (two parts SDS buffer, one part Triton dilution
buffer (100 mM Tris, pH 8.6, 100 mM NaCl, 5% (v/v) Tri-
ton X-100, 5 mM EDTA) and protease inhibitors (Roche).
Chromatin was sonicated (four times for 20 s, using a
Bandelin sonoplus sonicator (Bandelin electronic
GmbH&Co KG, Germany) to yield genomic DNA frag-
ments with a bulk size of 300–500 bp. Immunoprecipita-
ton was performed overnight at 4°C with polyclonal
antibodies specific for Smad4 (3 μg H-552 and C-20,
Santa Cruz). Immune complexes were recovered by add-
ing 50 μL magneto-beads (Dynal, Invitrogen) and incu-Page 3 of 13
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as described previously [19]. Washed precipitates were
incubated overnight at 65°C in elution buffer (TE, 1%
SDS, 0.1 M NaHCO3) to reverse the formaldehyde
crosslinking. DNA fragments were purified with a
QiaQuick Spin Kit (Qiagen) according to the manufac-
turer's recommendations except that the samples were
first mixed with agitation for 30 min with PB buffer. The
promoter regions were amplified from 2 μL of the
extracted DNA per reaction and using primers listed in
additional file 1 in 32 cycles of amplification to yield frag-
ments of ~200 bp length.
Northern blot analysis
RNA was isolated with a commercial kit (Qiagen). North-
ern blots and hybridizations were performed as described
previously [17]. AP1 probes were prepared by RT-PCR
from cell line RNA, using primers listed in additional file
1. For loading control blots were stripped and reprobed
for GAPDH. Signal intensities were quantified by Phos-
phorImage analysis (Packard).
Results
Stable reexpression of Smad4 by retroviral transduction 
restores TGFβ responsiveness in human SW480 colorectal 
and BxPC3 pancreatic carcinoma cells
We are using gene transfer techniques to address functions
of the tumor suppressor gene Smad4 in human cancer
cells. Previously, we have established Smad4-positive
derivatives from the colon carcinoma cell line SW480 by
stable transfection. This cell model proved that reexpres-
sion of Smad4 at subphysiological levels was adequate to
suppress tumor growth whereas TGFβ resistance of the
cells was retained. Rather, Smad4 induced mesenchymal
to epithelial reversion through induction of E-cadherin
[15,17]. We also found that Smad4-positive SW480 cells
in contrast to Smad4-negative clones deposited an adhe-
sive matrix in vitro on tissue culture plastic. Based on this
observation we identified the heterotrimeric BM compo-
nent LM-332 as a novel target structure of Smad4. In pan-
creatic carcinoma cells BxPC3 and CFPAC-1, Smad4
reexpression also increased constitutive LM-332 expres-
sion levels and additionally restored TGFβ induction of
LM-332 [19].
In SW480 cells TGFβ responses through the canonical
pathway are restricted by very low expression levels of the
TGFβ type II receptor; Smad4-positive SW480 cells dis-
played TGFβ responsiveness of the p3Tplux promoter in
cotransfections with a constitutively active TGFβ type I
receptor construct, only [17]. As these stably transfected
SW480 cell clones express "subphysiological" Smad4 lev-
els (roughly one third of "normal" endogenous levels in
Smad4-positive cell lines), we asked if higher Smad4 lev-
els as previously obtained through retroviral gene transfer
in Smad4-deficient pancreatic carcinoma cells (i.e.
BxPC3) were adequate to overcome the limiting receptor
levels in SW480 cells. In fact, a novel set of Smad4-posi-
tive retrovirally transduced SW480 derivatives showing
moderate overexpression of Smad4 (roughly threefold of
"normal" endogenous levels in Smad4-positive Paca44
cells, Fig. 1A) displayed strong TGFβ responsiveness in
transient transfection assays with p3Tplux (5–6 fold
induction) and p6SBE (40 fold induction) promoter
reporter constructs (Fig. 1B).
Smad4-positive BxPC3 cell clones display significantly
higher activities of both reporter constructs in the absence
and in the presence of exogenous cytokine when com-
pared to Smad4-positive SW480 cells. This may be due to
different levels of autocrine TGFβ (family) cytokines
expressed by both cell lines. Moreover, we have shown
previously in SW480 cells, unlike BxPC3, that very low
expression levels of the TGFβ type II receptor restrict TGFβ
responsiveness [15].
We then analyzed TGFβ responses of the endogenous
genes encoding LM-332 through Northern blot analysis.
The results confirmed that moderate overexpression of
Smad4 was adequate to restore TGFβ responsiveness of
LM-332 in SW480 and BxPC3 cells (Fig. 1C).
Promoter-reporter constructs of the LAMA3, LAMB3 and 
LAMC3 genes reflect Smad4-dependent LM-332 induction 
of endogenous genes
To unravel molecular mechanisms and pathways involved
in Smad4-mediated positive regulation of the LAMA3,
LAMB3 and LAMC2 genes, we here set up detailed pro-
moter analyses. An in silico sequence analysis using MatIn-
spector software [33,34] confirmed that the previously
analyzed SBE element at -1.5 kb is the single SBE site in a
5 kb fragment upstream of the transcription start site of
the LAMA3 gene [19] and indicated that both, the LAMB3
and the LAMC2 promoters harbor three putative SBE sites
approximately at -1.41; 2.66 and 3.67 and at -1.59; 2.67
and 3.85 kb, respectively. Thus, we amplified 4 kb pro-
moter regions from the three LM-332 promoters and
cloned them into the pGL3 basic luciferase promoter vec-
tor. Next, the activities of the promoter-reporter constructs
were tested in Smad4-negative and Smad4-positive clones
of the SW480 and BxPC3 cell lines as well as in the
Smad4-positive colorectal adenoma cell line LT97 in the
absence and in the presence of TGFβ. All three constructs
displayed increased constitutive activities in the Smad4-
positive derivatives and all of them mediated Smad4-
dependent TGFβ induction (Fig. 2) thus reflecting
responses of the endogenous genes (Fig. 1C, [19]).Page 4 of 13
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promoter is mediated via an SBE site at -1.5 kb and via 
downstream AP1 sites
The 4 kb (Fig. 2) and the 2 kb LAMA3 promoter constructs
displayed very similar responses in all three cell lines ana-
lyzed (data not shown). Thus, we used the 2 kb construct
for further analyses, which contains the single SBE site
(Fig. 3, construct a). Mutational inactivation of the SBE
site at -1.5 kb (construct b) did not affect the Smad4-
dependent increase of constitutive promoter activity.
Moreover, the mutant construct still mediated approxi-
mately half of the TGFβ response as compared to the
wildtype construct. Thus, we asked for additional pro-
moter sequences involved in Smad4-dependent transcrip-
tional regulation of LAMA3 expression. Three AP1
binding sites close to the transcription start site at posi-
tions -90, -146 and -272 in the human promoter confer
epithelial specific expression [35] and have also been
implicated in the TGFβ response of the mouse promoter
[31]. Moreover, AP1 transcription factors are known to
interact with Smad proteins [36-38]. A construct with all
three AP1 sites mutated displayed a reduction of basal
promoter activity as expected (construct c). The reduction
was moderate in SW480 cells and very pronounced in
LT97 and BxPC3 cells which both display epithelial mor-
phology. Levels of Smad4-dependent constitutive and
TGFβ-induced activity were reduced correspondingly.
Interestingly, when both, mutation of the SBE site and
mutation of the AP1 sites were combined, the TGFβ
response was completely abolished (construct d), suggest-
ing that Smad4 cooperates with AP1 transcription factors
in TGFβ-induced LAMA3 induction.
Each of the putative SBE sites in the LAMB3 and LAMC2 
promoter is non-functional
To the best of our knowledge functional analyses of the
LAMB3 promoter except for methylation studies have not
yet been published. As the in silico sequence analysis indi-
cated a putative SBE site at position -1413 we first cloned
a 2 kb promoter fragment into the reporter vector (Fig 4A,
construct a). This construct reflected the Smad4-depend-
ent increase in basal expression levels but did not display
TGFβ induction neither in SW480 cells (Fig. 4) nor in
BxPC3 cells (data not shown). Moreover, mutation of the
putative SBE site at -1.41 kb (construct b) did not alter
reporter responses neither in SW480 cells (Fig. 4) nor in
BxPC3 cells (data not shown) suggesting that this site is
not functional. Next, as two additional putative SBE sites
were indicated at positions -2.66 and -3.67 kb, we cloned
a reporter construct harboring approximately 4 kb of the
LAMB3 promoter (construct c). This construct did show
induction in response to TGFβ in all TGFβ responsive cell
lines analyzed and thus reflected endogenous gene
responses (Fig. 1C, Fig. 2). Surprisingly, however, both of
these SBE sites also proved non-functional; as for the SBE
site at -1.41 kb mutation of the SBE sites at positions -2.66
and -3.67 kb did not alter reporter responses in transient
transfections of SW480 cells (constructs d, e) and other
TGFβ responsive cell lines (Smad4-reconstituted BxPC3,
LT97, Hacat; data not shown).
Restoration of TGFβ responsiveness through reexpression of Smad4Figure 1
Restoration of TGFβ responsiveness through reex-
pression of Smad4. Smad4 expression was stably restored 
by retroviral transduction in Smad4-deficient human SW480 
colon carcinoma and BxPC3 pancreatic adenocarcinoma 
cells. A Western blot analysis for the human Smad4 protein 
on total protein extracts of each three Smad4-negative and 
Smad4-positive clones of SW480 and BxPC3 cells, respec-
tively (TJ: empty vector control clones, DTJ: Smad4- (DPC4) 
positive clones, Paca44 as a representative cell line to com-
pare for "normal" endogenous expression levels). B Tran-
sient transfections with p3Tplux and p6SBE reporter vectors. 
Normalized promoter activity of p3Tplux (a fusion construct 
of the PAI-1 and collagenase-1 promoters harboring AP1 
sites) and p6SBE (a 6fold concatemer of the SBE site) as ana-
lyzed in transient transfections of TGFβ-treated (24 h) and -
untreated Smad4 negative and Smad4 reexpressing cells. 
Experiments were repeated in triplicates with the three 
clones shown in Fig. 1A and bars show the mean values with 
the standard error of the mean. C Reexpression of Smad4 in 
Smad4-deficient human colon and pancreatic carcinoma cells 
leads to increased basal and/or TGFβ induced laminin-332 
expression. Quantification by phosphor image analysis of 
Northern blot results with RNAs prepared from TGFβ-
treated (24 h) or -untreated Smad4-negative and Smad4-pos-
itive SW480 (mean value of each three clones analyzed in 
two approaches) and BxPC3 (mean value of each two clones 
in two separate approaches) cells, normalized to GAPDH 
expression.Page 5 of 13
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Transient transfections with 4 kb promoter fragments of the three genes encoding LM-332Figur  2
Transient transfections with 4 kb promoter fragments of the three genes encoding LM-332. Normalized pro-
moter activity as analyzed in transient transfections of each three Smad4-negative and Smad4-reexpressing SW480 and BxPC3 
clones and of Smad4-positive LT97 adenoma cells. Bars show the mean value with the standard error of the mean. All three 
promoter constructs displayed increased constitutive activities in the Smad4-positive derivatives and all of them mediated 
Smad4-dependent TGFβ induction.
BMC Cancer 2008, 8:215 http://www.biomedcentral.com/1471-2407/8/215The 4 kb promoter construct (Fig 4B, construct a') of the
LAMC2 promoter also reflected endogenous gene
responses to Smad4, namely Smad4-dependent increase
of constitutive expression and a less pronounced Smad4-
dependent TGFβ induction of LAMC2 expression (Fig. 1C,
2). The 4 kb region of the LAMC2 promoter harbors three
putative SBE sites, located at -1.59; -2.67 and -3.85 kb.
Functional regulatory sites were delimited by deletion and
mutation constructs (constructs b'-d'). Surprisingly, we
found, that a 0.8 kb promoter fragment still showed sim-
ilar activities in SW480 cells as compared to the 4 kb frag-
ment suggesting that all relevant regulatory sites reside
within this part of the promoter (construct e').
Smad4 effects on constitutive and TGFβ-induced promoter 
activities of LAMB3 and LAMC2 are conferred through 
AP1 and Sp1 sites
As all three putative SBE in the LAMB3 promoter did
prove non-functional, we then asked if AP1 sites may
mediate Smad4 effects on the LAMB3 promoter. AP1 sites
reside at positions -737 and -3520; both were mutated
separately and in combination. Mutation of the pro-
moter-proximal AP1 site reduced basal promoter activity
(in Smad4-negative cells) as well as Smad4-dependent
constitutive and TGFβ-induced promoter activity (Fig. 5A,
construct b vs. a). Mutation of the 3.5 kb AP1 site in con-
trast inactivated TGFβ responsiveness but did not alter
constitutive expression levels (construct c). Still, when
both mutations were combined, the Smad4-dependent
difference in basal activity of the LAMB3 promoter was
retained (construct d). Ultimately, we tested the Sp1 bind-
ing site indicated at position -99 by in silico sequence anal-
ysis. Mutation of this site on its own had no significant
Figure 3
Smad4-dependent TGFβ induction of the LAMA3 promoter is mediat d via an SBE and ownstream AP1 sitesFigure 3
Smad4-dependent TGFβ induction of the LAMA3 
promoter is mediated via an SBE and downstream 
AP1 sites. Normalized promoter activity of LAMA3 in 
Smad4-negative, Smad4-reexpressing and TGFβ-treated 
Smad4-positive SW480 and BxPC3 carcinoma cells as well as 
TGFβ-untreated and -treated Smad4-positive LT97 cells. 
Point mutations were introduced using the Quick-Change 
Site directed mutagenesis kit (Stratagene). Bars show the 
mean value of three approaches with the standard error of 
the mean. Mutational inactivation of the SBE site at -1.5 kb 
did not affect the Smad4-dependent increase of constitutive 
activity but reduced the TGFβ response to approximately 
half in all three cell lines tested (b). A mutation construct 
with all three AP1 sites mutated displayed a reduction of 
basal promoter activity (c). The reduction was moderate in 
SW480 cells and very pronounced in LT97 and BxPC3 cells. 
When both, mutation of the SBE site and mutation of the 
AP1 sites, were combined the TGFβ response was com-
pletely abolished (d).Page 7 of 13
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AP1 sites, however, the Smad4 effect on the LAMB3 pro-
moter activity was nearly completely abolished (construct
f vs. d).
On the LAMC2 promoter two neighboring AP1 sites at
positions -50 and -91 have been reported to mediate syn-
ergistic effects of HGF and TGFβ. Of note, these results
were obtained in HT29 colon carcinoma cells, which are
Smad4-negative [29]. Here we show, that in particular the
AP1-site at position -91 is involved in the Smad4 effect on
constitutive and on TGFβ-induced expression levels (Fig.
5B, construct a'-c'). As Smad4-dependent differences in
the construct with combined AP1 mutations are retained
(construct d'), we additionally analyzed the involvement
of the Sp1 site located at position -345 in the LAMC2 pro-
moter. Again, mutation of the Sp1 site on its own had no
significant effect (construct e'). When combined with the
mutated AP1 sites, however, all promoter activities were
strongly suppressed (construct f').
In summary, Smad4effects on constitutive and TGFβ-
induced LAMB3 and LAMC2 promoter activity in SW480
cells are mediated through AP1 sites and an Sp1 site
whereas SBE sites are non-functional in these promoters.
Chromatin-IP confirms Smad4 binding to AP1 sites in all 
three promoters but to an SBE site exclusively in the 
LAMA3 promoter
The comparison of promoter activities in Smad4-negative
and Smad4-reconstituted cells does not allow to differen-
tiate between direct effects (Smad4 binds to the respective
promoter region) and indirect effects (Smad4 may alter
Putative SBEs in the LAMB3 and LAMC2 promoters prove non-functionalFigure 4
Putative SBEs in the LAMB3 and LAMC2 promoters 
prove non-functional. Normalized and averaged promoter 
activity obtained from three experiments in Smad4-negative, 
Smad4-reexpressing and TGFβ treated Smad4-positive 
SW480 cells. While the -2 kb LAMB3 promoter did not con-
fer TGFβ responsiveness (a) and the mutation construct of 
the SBE at position -1.41 kb did not alter promoter 
responses (b), the -4 kb promoter displayed TGFβ induction 
(c). Mutational inactivation of both of the SBE sites at posi-
tions -2.66 and -3.67 kb did not significantly alter reporter 
responses in transient transfections (d, e). The -4 kb LAMC2 
promoter (a') as well as the -2 kb (c') and the -0.8 kb (e') pro-
moter constructs reflected endogenous gene responses; all 
of them retained TGFβ responsiveness. Correspondingly, 
mutations of the upstream SBE sites did not significantly 
affect TGFβ induction (b', d').
Smad4 effects on LAMB3 and LAMC2 promoter activities are conferr d through AP1 and Sp1 sitesFigure 5
Smad4 effects on LAMB3 and LAMC2 promoter 
activities are conferred through AP1 and Sp1 sites. 
Normalized and averaged LAMB3 and LAMC2 promoter 
activity obtained from three experiments in Smad4-negative, 
Smad4-reexpressing and TGFβ treated Smad4-reexpressing 
SW480 colon carcinoma cells (a). Mutation of the promoter-
proximal AP1 site reduced basal promoter as well as Smad4-
dependent constitutive and TGFβ induced LAMB3 promoter 
activity (b). Mutation of the 3.5 kb AP1 site inactivated TGFβ 
responsiveness but did not alter constitutive expression lev-
els (c). When both mutations (d) were combined with muta-
tion of the Sp1 site (e) the Smad4 effect on the LAMB3 
promoter activity was completely abolished (f). For the 
LAMC2 promoter a 0.8 kb fragment displayed increased con-
stitutive activities in Smad4-positive cells and mediated 
Smad4-dependent TGFβ induction (a'). Both AP1 sites are 
involved in the Smad4 effect on constitutive and TGFβ 
induced expression levels (b'-d'). When combined with the 
mutated Sp1 site (e') all promoter activities were significantly 
suppressed (f').Page 8 of 13
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factors). To get more insight into the underlying mecha-
nisms, we next we performed transient cotransfections of
a Smad4 expression construct with all three wild-type pro-
moter-reporter constructs into Smad4-deficient SW480
cells (data not shown). This led to increased promoter
activities to a similar extent as determined in the stable
Smad4-positive derivatives suggesting that all three LM-
332 genes are direct Smad4 target genes. Thus, we contin-
ued to assess direct binding of Smad4 to the respective
sites by chromatin IP.
We have shown in our previous work that LAMA3 is a
direct target gene of Smad4. Chromatin IP has confirmed
Smad4 binding to the SBE region in the endogenous
LAMA3 promoter [19]. In this work we demonstrated that
the promoter-proximal AP1 sites are additionally
involved in conferring TGFβ responsiveness to the LAMA3
promoter in a Smad4-dependent manner (see Fig. 2, 3
construct c). Consistent with this result, Smad4 binding to
this region could also be demonstrated by chromatin IP
(Fig. 6). PCR amplification of an upstream region per-
formed as a negative control failed.
Putative SBE sites in the LAMB3 and LAMC2 promoters,
investigated with transient transfections, proved non-
functional. Correspondingly, all attempts to show Smad4
binding to the respective promoter regions failed. In con-
trast, direct binding of Smad4 – presumably in complex
with AP1 family transcription factors [36,38] – to the pro-
moter regions with functional AP1 sites could be demon-
strated (Fig. 6). In conclusion, results from chromatin IP
experiments are consistent with promoter analyses
through transient transfections of reporter constructs
throughout. The involvement of functional binding sites
in basal promoter activity, Smad4-dependent constitutive
gene expression and Smad4-mediated TGFβ responses is
summarized in Figure 7.
Smad4 mediates transcriptional induction of AP1 family 
members in response to TGFβ
Genes encoding AP1 family members have previously
been characterized as TGFβ-responsive [39]. Thus, we ana-
lyzed transcriptional responses to TGFβ in Smad4-defi-
cient and Smad4-reexpressing SW480 cells as well as in
Smad4-positive LT97 colorectal adenoma cells (Fig. 8).
Expression levels of c-jun, junB, junD, c-fos, fosB and fra-
1 remained unaffected by the addition of recombinant
TGFβ in Smad4-deficient SW480 cells (fra-2 not
expressed). Smad4-reexpressing SW480 cells, however,
displayed increased transcript levels of c-jun, junB, junD,
fosB and fralin response to TGFβ as did LT97 cells (with
the exception of fosB and fra1). Interestingly, expression
of c-fos was downregulated in Smad4-positive SW480
cells but strongly upregulated in LT97 cells. Whereas
TGFβ-induced binding of Smads to promoter elements in
the c-jun and junB promoters has been reported earlier
[37,40] the involvement of Smad4 in transcription regula-
tion of other AP1 family members is a novel finding. Our
findings suggest, that "indirect" effects of Smad4, namely
altered expression patterns of AP1 family members, may
impinge on Smad4 target genes, among them the genes
encoding LM-322.
Discussion
Molecular mechanisms and target genes through which
Smad4 mediates its tumor suppressor function are still
incompletely understood. We have previously reported
that Smad4 is a positive regulator of the three genes which
encode for the heterotrimeric Laminin-332 (LM-332)
molecule, a prominent component of basement mem-
Chromatin-Immunoprecipitation (ChIP) indicates that Smad4 binds to all three promoters of LM-322Figure 6
Chromatin-Immunoprecipitation (ChIP) indicates 
that Smad4 binds to all three promoters of LM-322. 
Chromatin prepared from Smad4-negative, Smad4-reex-
pressing and TGFβ-treated Smad4-reexpressing BxPC3 cells 
was shared to obtain fragments of 300–500 bp length, immu-
noprecipitated and used for PCR amplification of ~200 bp 
promoter fragments. Input chromatin after sharing is directly 
used for PCR amplification as a control. Binding of Smad4 to 
the LAMA3 promoter region which harbors the SBE could 
repeatedly be shown as well as to the regions which incorpo-
rate the functional AP1 sites in all three promoters. 
Attempts to show binding of Smad4 to other regions within 
the 4 kb LM-332 promoters failed.Page 9 of 13
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tumor cells led to secretion and deposition of the heterot-
rimeric molecule in BM-like structures and was associated
with reversion from mesenchymal-like to epithelial mor-
phology, with suppression of invasiveness in vitro and
suppression of tumor growth in vivo [15-19]. Expression
control of an essential BM component thus constitutes an
important function of the tumor suppressor Smad4.
Smad4 is the central mediator of TGFβ responses through
the canonical TGFβ/Smad signal cascade. Smad4 is the
single co-Smad that forms complexes with receptor-
Smads, which then translocate into the nucleus where
they bind to Smad binding elements (SBE) in the pro-
moter region of target genes. In addition, Smad complexes
can be targeted to DNA by interacting with ubiquitous
sequence-specific DNA-binding transcription factors like
AP1 and Sp1 [22]. TGFβ, in addition to the canonical
pathway activates further signal cascades like the MAPK/
JNK pathways, which in turn can be modified through
cross-talk with the Smads [24,25].
Addressing the molecular mechanisms through which
Smad4 mediates transcriptional regulation of the three
LM-332 genes we here provide evidence for three different
mechanisms: First, Smad4 binds to a functional SBE site,
this mechanism is operative in the LAMA3 promoter,
exclusively. Secondly, Smad4 binds to AP1 (and Sp1) sites
in all of the three promoters presumably via interaction
with AP1 family components and lastly, Smad4 mediates
transcriptional induction of AP1 factors. As AP1 sites are
intimately involved in transcriptional regulation of lam-
inin genes this Smad4 impact on AP1 factors may repre-
sent an important, though indirect mechanism of how
Compilation of functionally important bindings sites in the three LM-332 promotersFigure 7
Compilation of functionally important bindings sites 
in the three LM-332 promoters. This scheme shows a 
summary of results reflecting the complexity of promoter 
regulation of LM-322. Indicated in the three promoters are 
the binding sites with significant importance for basal pro-
moter activity "B"; for Smad4 dependent constitutive activity 
"SC" and for Smad4 dependent TGFβ induction "ST". In addi-
tion, binding of Smad4 as confirmed with ChIP analysis is indi-
cated on top of the promoters.
Smad4 mediates transcriptional induction of AP1 family members in response to TGFβFigur  8
Smad4 mediates transcriptional induction of AP1 
family members in response to TGFβ. Total RNA from 
Smad4-deficient and Smad4-reexpressing SW480 cells and 
Smad4-positive LT97 colorectal adenoma cells was hybrid-
ized with specific probes for AP1 family members. Results 
were confirmed twice with similar results. Expression levels 
remained unaltered by the addition of recombinant TGFβ in 
Smad4-deficient SW480 cells. In contrast, all of these genes 
except for c-fos displayed increased mRNA levels in Smad4-
reexpressing SW480 cells in response to TGFβ. Expression 
of c-fos appeared to be downregulated in Smad4-positive 
SW480 cells but strongly upregulated in LT97 cells.Page 10 of 13
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absence of direct binding at the respective promoters.
Whereas Smad4 increases constitutive expression levels
and TGFβ responses of all three genes encoding LM-332,
the underlying mechanisms are surprisingly complex and
substantially diverse. To start to decipher mechanisms
and pathways involved we here used transient transfec-
tion assays using promoter-reporter constructs and
showed that their activities strictly reflected responses of
the endogenous genes. The colorectal adenoma cell line
LT97 used as a model for premalignant cells displayed
increased expression of all three LM-332 genes in
response to TGFβ. Likewise, SW480 colorectal and BxPC3
pancreatic carcinoma cells showed transcriptional induc-
tion of all three genes in a Smad4-dependent manner,
whereas their Smad4-negative counterparts remained
unaffected by TGFβ treatment. The LAMA3 promoter,
only, harbored a functional SBE at -1.5 kb mediating
Smad4-dependent TGFβ induction of LAMA3 promoter
activity. In addition, downstream AP1 sites were shown to
be involved in basal promoter activity and, in combina-
tion with the SBE, to mediate Smad4-dependent constitu-
tive and TGFβ-induced promoter activity.
The LAMB3 promoter to our knowledge has not yet previ-
ously been characterized. We here report that three puta-
tive SBE sites surprisingly proved non-functional through
the analysis of mutation and deletion constructs. Rather,
mutation of an AP1 site at -737 in the LAMB3 promoter
reduced basal promoter activity and mutation of a second
AP1 site at -3.5 kb abrogated TGFβ responsiveness. Muta-
tion of a promoter proximal Sp1 site did not show signif-
icant effects on its own, but combined mutations of the
Sp1 and both AP1 sites fully suppressed Smad4 effects on
basal and TGFβ-induced promoter activities. Likewise,
Smad4-dependent regulation of the LAMC2 promoter
was mediated through two AP1 sites and an Sp1 site resid-
ing within a 350 bp downstream promoter region. Of
note, whereas Sp1 sites are involved in positive regulation
of both the LAMB3 and LAMC2 promoters, the LAMA3
promoter with a downstream Sp1 site mutated displayed
strongly increased activity suggesting that in the LAMA3
promoter the Sp1 site exerts transcriptional repression
(data not shown).
Chromatin immunoprecipitation showed TGFβ-induced
binding of Smad4 to the functional SBE in the LAMA3
promoter and to the promoter regions harboring func-
tional AP1 sites in each of the three promoters, confirm-
ing that all three genes encoding LM-332 are direct Smad4
target genes. Binding of Smad4 to AP1 sites may work via
interaction of Smads with AP1 transcription factors as pre-
viously shown in the regulation of collagenase-I [38],
MMP1 [40], interleukin-11 [41] and demonstrated by Lib-
erati et al. [37] and Yamamura et al [42].
In addition, expression analysis of AP1 family transcrip-
tion factors revealed Smad4-dependent transcriptional
induction in response to treatment with TGFβ indicating
that direct and indirect mechanisms may converge on
these three promoters to regulate LM-332 expression. Of
note, whereas TGFβ induced binding of Smads to pro-
moter elements in the c-jun and junB promoters has been
reported earlier [37,43] the involvement of Smads in tran-
scriptional regulation of other AP1 family members is a
novel finding in this work.
Interestingly, the dual interdependence of Smad4 and
AP1 factors is not without precedence. Our data suggest
that Smad4, both, impinges on the regulation of AP1
expression as well as depends on AP1 factors for binding
to AP1 sites. Likewise, it has been shown earlier that the
androgen receptor drives the expression of ETS transcrip-
tion factors and can then be co-dependent on ETS factors
for its recruitment to a subset of promoters [44].
We do not yet know if all of these Smad4 effects are medi-
ated through the canonical TGFβ/Smad signaling path-
way. TGFβ can also activate the MAPK pathway among
others [24,25]; phosphorylation and activation of AP1
proteins through the MAPkinase pathway has been
described long ago [45]. However, all of the TGFβ effects
observed in our cell models are dependent on Smad4. So,
if other signal cascades in addition to the canonical path-
way were involved in transcriptional regulation of the
laminin genes in SW480 and BxPC3 cells these also func-
tion in a strictly Smad4-dependent manner.
We are only beginning to decipher Smad4 functions in
cellular signaling networks. Here, we addressed molecular
mechanisms underlying Smad4-dependent regulation of
constitutive (cell-autonomous) and of TGFβ-induced
transcription of laminin genes. Of note, although Smad4
is a positive regulator of all three LM-332 chains the
underlying mechanisms are surprisingly complex and
binding sites involved are divergent for the LAMA3 pro-
moter on the one hand and for the LAMB3 and LAMC2
promoters on the other side. We hypothesize that this
divergence in modular regulation of the three promoters
may lay the ground for uncoupled regulation of LM-332
at the invasive front of tumors where an intracellular accu-
mulation of the γ2-chain can often be observed and repre-
sents an impressive molecular marker [46-49]. Invading/
budding tumor cells are maximally exposed to cytokines
expressed by stromal cells at the invasive front. For exam-
ple, monocytes/macrophages present in many tumors at
high numbers are a major source not only for TGFβ but
also for TNFα [50,51]. Interestingly, Korang et al. reported
that TNFα in epidermal keratinocytes inhibited LAMA3
but not LAMB3 and LAMC2 transcription [26]. We also
observe uncoupled responses of the three LM-332 genes
to TNFα in Smad4-deficient but not in Smad4-positivePage 11 of 13
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that loss of Smad4 may also contribute to uncoupled reg-
ulation of LM-332 and consequently to an intracellular
accumulation of the γ2-chain. NF-kB binding sites medi-
ating TNFα responses through the canonical pathway are
present in all three promoters but have not yet been func-
tionally analyzed. In addition, TNFα can also signal
through Sp1 [52] and through AP1 binding sites [45]
which we have shown here to be implicated in Smad4-
dependent transcriptional regulation of the laminin
genes.
Conclusion
In summary, whereas Smad4 is a positive regulator of
basal and of TGFβ-induced promoter activities of the
three LM-332 genes, the underlying mechanisms are sur-
prisingly complex and significantly differ between the
three promoters. Uncoupled regulation, namely induc-
tion of the LAMC2 but not the LAMA3 gene in response to
signals derived from the tumor stroma at the invasive
front of tumors is an important issue in tumor biology.
We here show that multiple transcription factors and
binding sites are involved in transcriptional regulation of
the LM-332 genes. At least some of them, i.e. components
of the AP1 family, are well known to be targeted through
cytokines other than TGFβ, cytokines, which may also be
present in the microenvironment of invasive tumor cells.
Thus, it will be interesting in the future to address the
impact of the Smad4 status of tumor cells on transcrip-
tional responses in the context of various environmental
stimuli.
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